Search

Artificial intelligence is rapidly entering pharmaceutical manufacturing through predictive analytics, process analytical technology, continuous manufacturing platforms, and data-driven quality control. These developments promise earlier detection of process deviation, adaptive optimization of critical process parameters, and more responsive assurance of critical quality attributes. Yet the dominant regulatory and quality vocabulary remains anchored in Quality-by-Design, a paradigm built around pre-defined knowledge, structured risk assessment, and validated control strategies. The central problem is that AI-assisted manufacturing systems do not behave like conventional pharmaceutical processes governed solely through fixed design spaces. Machine learning models may change performance as data distributions shift, as sensors age, as materials vary, or as feedback loops alter the operating environment. This creates a governance gap between the static logic of pre-validation and the dynamic reality of algorithmic decision-making. This critical conceptual review examines whether Quality-by-Design remains sufficient for AI-assisted pharmaceutical manufacturing. It argues that QbD is still necessary but no longer sufficient because it was designed for processes whose boundaries, models, and control logic can be defined before routine operation. AI-assisted systems require an additional governance logic capable of supervising data, models, explanations, adaptation, and accountability throughout the product lifecycle. The review develops the concept of Quality-by-Intelligence as a forward-looking governance framework. QbI does not discard QbD; rather, it extends it by embedding data stewardship, model lifecycle management, explainable decision-making, adaptive risk control, and regulatory translation into the pharmaceutical quality system. Its purpose is to govern not only the manufacturing process, but also the intelligence layer that increasingly mediates quality decisions. Quality-by-Intelligence reframes pharmaceutical quality as an adaptive, evidence-generating, and accountable system rather than a one-time design achievement. The transition will require new regulatory expectations, new validation evidence, new operator competencies, and stronger collaboration between industry, regulators, and academic experts. Without this shift, AI may be deployed into manufacturing faster than the quality systems needed to govern it.

Digital twins promise to reshape pharmaceutical development and manufacturing by creating virtual replicas that mirror physical systems over time. Their value lies in linking process knowledge, real-time data, predictive modelling, and decision support into a single operational framework. In pharmaceutical contexts, this promise is especially relevant because product quality is tightly coupled to process history, material attributes, and patient-facing performance. The core problem is that digital twin development in pharma remains fragmented across manufacturing, drug delivery, regulatory modelling, and digital transformation literatures. Manufacturing studies often focus on process control, PAT, and continuous production, whereas drug delivery studies emphasise physiological prediction, formulation performance, and patient-specific behaviour. These areas share mechanistic foundations, but they are rarely treated as parts of a unified pharmaceutical digital twin ecosystem. This conceptual review analyses digital twin logic across pharmaceutical manufacturing and drug delivery systems. It focuses on how mechanistic models, hybrid modelling, and real-time data infrastructures can be combined to support quality, performance prediction, and regulatory decision-making. The central argument is that digital twins must become not only predictive but also explainable and governable. The synthesis defines the architecture of pharmaceutical digital twins, catalogues their manufacturing and drug delivery applications, and identifies unresolved challenges in model coupling, parameter identifiability, uncertainty handling, and regulatory credibility. It also maps technological, organisational, economic, and regulatory barriers that prevent promising models from becoming routine industrial tools. Five tables summarise the conceptual architecture, application domains, model architectures, integration problems, and implementation barriers. Realising the full potential of pharmaceutical digital twins will require mechanistic rigour, explainable analytics, high-quality data connectivity, and early alignment with regulatory expectations. The future of the field will depend less on isolated demonstrations and more on reusable validation strategies, transparent model governance, and cross-sector collaboration. Digital twins should therefore be understood as evolving regulatory-scientific infrastructures rather than as standalone computational artefacts.

Continuous manufacturing has been promoted as a transformative alternative to batch pharmaceutical production because it can reduce equipment footprint, shorten development-to-commercialisation timelines, and enable more responsive quality assurance. Its appeal rests on the idea that material flows through an integrated process rather than waiting in isolated unit operations. Yet the technical maturity required to make that flow reliable is often understated. The central problem is that continuous operation is sometimes treated as intrinsically superior to batch production, as though continuity alone guarantees better quality. In practice, quality depends on the ability of sensors, models, actuators, supervisory logic, and operators to detect and correct deviations fast enough to prevent poor material from propagating through the line. Without that control capability, continuous systems may amplify rather than resolve process vulnerability. This critical review examines continuous pharmaceutical manufacturing through three linked lenses: control architecture design, process robustness, and regulatory translation. It asks whether current systems are sufficiently controlled to justify claims of superior quality, whether robustness is assessed with appropriate metrics, and whether regulatory frameworks have matured enough to support dynamic manufacturing strategies. The review deliberately treats continuous manufacturing as a socio-technical system rather than as a purely technological upgrade. The evidence indicates that continuous manufacturing has advanced substantially, particularly in direct compression, wet granulation, process analytical technology, residence-time modelling, soft sensing, and model predictive control. However, many demonstrations remain limited by narrow disturbance scenarios, incomplete treatment of start-up and shutdown, uncertain model maintenance requirements, and uneven translation into routine good manufacturing practice. Regulatory acceptance is progressing, but unresolved questions remain around batch definition, traceability, adaptive control validation, and lifecycle change management. The review concludes that continuous manufacturing is not an automatic guarantor of pharmaceutical quality. Its value depends on control-centric process design, standardised robustness assessment, credible digital and analytical infrastructure, and regulatory alignment that recognises dynamic process operation. The future pathway requires stronger pre-competitive collaboration, more realistic stress testing, and regulatory science that keeps pace with advanced control strategies.

Continuous pharmaceutical manufacturing has matured from a technical alternative to batch production into a strategically important manufacturing paradigm. Its promise lies in integrated material flow, smaller production footprints, improved process understanding, flexible scale-out, and the possibility of real-time quality assurance. Yet the quality systems used to govern continuous manufacturing often remain conceptually anchored in batch-era assumptions. The central problem addressed in this article is the mismatch between continuous manufacturing’s dynamic data environment and the inherited quality logic of discrete batch testing, fixed specifications, and retrospective release decisions. In batch quality logic, quality is often treated as a property confirmed after production. In continuous manufacturing, however, quality must be interpreted, predicted, and controlled while the process is still unfolding. This article proposes Lifecycle Intelligence as a theory-driven model for rethinking quality in continuous pharmaceutical manufacturing systems. Lifecycle Intelligence is defined as a quality paradigm in which process data, predictive models, control strategies, and lifecycle learning mechanisms are integrated to maintain quality dynamically across development, validation, commercial production, and post-approval improvement. The model shifts attention from isolated product release to continuous quality cognition. The argument advanced is that continuous manufacturing cannot reach its full quality and regulatory potential if it is governed primarily by batch quality logic. A lifecycle intelligence paradigm is needed to convert continuous data streams into validated quality decisions. This shift will require not only technical advances, but also new validation practices, model governance structures, regulatory dialogue, and workforce capabilities.

Digital twin technology is increasingly used across pharmaceutical science, pharmaceutical manufacturing, precision medicine, and regulatory science. However, the same term is now applied to systems with very different simulated objects, including drug products, manufacturing processes, patients, and regulatory workflows. This semantic expansion has created a need for clearer conceptual organisation. The central problem addressed in this article is that pharmaceutical digital twin research has developed faster than its classification language. A tablet dissolution model, a continuous manufacturing simulator, a virtual patient population, and a compliance-monitoring model may all be described as digital twins, even though they support different decisions and require different validation logics. Without classification, comparison across studies becomes imprecise. This article proposes a four-category taxonomy of pharmaceutical digital twin systems. The categories are Product Twins, Process Twins, Patient Twins, and Regulatory Twins. The classification is grounded in the primary object of simulation and the principal decision function supported by the twin. The proposed taxonomy shows that digital twins should not be treated as a single technological class. Product Twins primarily simulate drug-product behaviour, Process Twins simulate manufacturing operations, Patient Twins simulate therapeutic response in individuals or populations, and Regulatory Twins simulate or support regulatory evaluation and oversight. Distinguishing these categories is a necessary step toward mature pharmaceutical digital twin science.

Pharmaceutical manufacturing is moving from automated equipment and digitally assisted control toward more autonomous systems capable of interpreting process data, adjusting operating conditions, and supporting quality decisions. This trajectory promises faster response, improved consistency, and more adaptive control across complex production environments. Yet autonomy also changes the nature of manufacturing responsibility because technical decisions increasingly occur inside algorithmic systems rather than through visible human judgement alone. The central problem addressed in this article is the trust deficit created by autonomous pharmaceutical manufacturing. When an algorithm modifies a critical process parameter, detects an anomaly, recommends batch continuation, or contributes to a quality disposition, regulators, operators, quality units, and patients require confidence that the decision remains safe, explainable, reversible, and accountable. Trust cannot be assumed simply because the system performs well during validation; it must be sustained over time as processes, materials, sensors, models, and organisational practices evolve. This article develops an original theory-driven framework for trustworthy autonomous pharmaceutical manufacturing. The framework is structured around three interdependent pillars: human oversight, model drift management, and quality accountability. These pillars are treated not as separate compliance add-ons but as mutually reinforcing design requirements for autonomous manufacturing systems operating in Good Manufacturing Practice environments. The article draws on a theoretical synthesis of peer-reviewed literature on pharmaceutical manufacturing automation, process analytical technology, machine learning, trust in automation, human–autonomy teaming, resilience engineering, socio-technical systems, and model drift. It reframes autonomous manufacturing as a socio-technical trust problem rather than a purely technical optimisation problem. Four tables map the theoretical foundations, oversight architectures, drift-management logic, and integrated Trustworthy System Framework. The proposed framework argues that trustworthiness in autonomous pharmaceutical manufacturing is not a property of an algorithm alone. It emerges from the designed relationship among people, models, process controls, quality systems, audit trails, and governance responsibilities. Autonomous manufacturing will become viable only when the system can remain technically reliable, humanly overseen, and institutionally accountable throughout its lifecycle.